Compare SKYW & TLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SKYW | TLX |
|---|---|---|
| Founded | 1972 | 2015 |
| Country | United States | Australia |
| Employees | N/A | 1184 |
| Industry | Air Freight/Delivery Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.5B | 3.6B |
| IPO Year | 1994 | N/A |
| Metric | SKYW | TLX |
|---|---|---|
| Price | $99.72 | $11.18 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 4 |
| Target Price | ★ $123.67 | $21.13 |
| AVG Volume (30 Days) | ★ 432.9K | 212.0K |
| Earning Date | 04-23-2026 | 08-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 33.20 | N/A |
| EPS | ★ 2.50 | N/A |
| Revenue | ★ $2,971,963,000.00 | N/A |
| Revenue This Year | $8.35 | N/A |
| Revenue Next Year | $3.55 | N/A |
| P/E Ratio | ★ $40.00 | $150.33 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $77.89 | $6.28 |
| 52 Week High | $123.94 | $16.85 |
| Indicator | SKYW | TLX |
|---|---|---|
| Relative Strength Index (RSI) | 64.92 | 55.64 |
| Support Level | $95.25 | $9.46 |
| Resistance Level | $101.95 | $11.38 |
| Average True Range (ATR) | 2.80 | 0.28 |
| MACD | 0.05 | 0.06 |
| Stochastic Oscillator | 83.14 | 53.41 |
SkyWest Inc offers commercial air services in the United States, Canada, Mexico, and the Caribbean. Additionally, it leases aircraft to capable users to help generate revenue. SkyWest generally provides regional flights and utilizes smaller, lower-cost aircraft to carry passengers who book tickets through partner airlines. It partners with carriers to fly and operate aircraft for a fee and may use the carriers' brands and ground support to coordinate marketing and transport passengers. The company has two reportable segments: SkyWest Airlines and SWC, which generate maximum revenue, and SkyWest Leasing activities.
Telix develops radiopharmaceuticals to manage cancer. Radiopharmaceuticals are radioisotopes bound to molecules that can target specific cells. At low doses, these drugs can bind to specific cancer cells with radiation, and then positron emission tomography imaging can accurately visualize tumors. At high doses, these drugs can selectively target and treat tumors with radiation, known as radioligand therapy. Radiopharmaceuticals are usually injected into the bloodstream. Telix has a pipeline of potential radiopharmaceuticals but currently earns most of its revenue from US sales of Illuccix, largely used as an imaging agent to visualize the spread of prostate cancer.